gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor–positive breast cancer in premenopausal patients: a randomised, trial (GABG trial IV-A-93)

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Sabine Vescia - German Breast Group, Neu-Isenburg, Deutschland
  • Erika Graf - Universitätsklinikum, Freiburg
  • Matthias Geberth - Universitätsklinikum, Heidelberg
  • Wolfgang Eiermann - Rot-Kreuz Krankenhaus, München
  • Walter Jonat - Universitätsklinikum, Kiel
  • Bettina Conrad - Senologisches Zentrum, Kassel
  • Klaus Brunnert - Klinik für Senologie, Osnabrück
  • Bernd Gerber - Universitätsklinikum, Frankfurt a.M.
  • Manfred Kaufmann - Universitätsklinikum, Frankfurt a.M.
  • Gunter von Minckwitz - German Breast Group, Neu-Isenburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO035

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk145.shtml

Published: March 20, 2006

© 2006 Vescia et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

We investigated gonadotropin-releasing hormone analogues as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer. Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n = 378) or goserelin every 28 days for 2 years (n = 393). During a median follow up of 4.9 years, 123 events were observed. The first-failure event of CMF vs. goserelin, respectively, was ipsilateral locoregional recurrence (18 vs. 20), contralateral breast cancer (7 vs. 6), distant failure (35 vs. 24), and death without recurrence (2 vs. 2). Forty-two (23 vs. 19) deaths of any cause occurred. The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI = 0.54–1.14; P = 0.19). Treatment effect favoured goserelin in grade 1 or 2 tumours and tumours of ≤ 20 mm in size. We conclude that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer.